Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$2.71 USD

2.71
5,620,671

+0.20 (7.97%)

Updated Aug 10, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 252)

Industry: Medical - Instruments

Trades from $1

Zacks News

OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss

OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.

OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.

OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top

OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.

OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Tops Q1 Earnings and Revenue Estimates

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.

OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know

OPKO Health (OPK) closed the most recent trading day at $3.51, moving +0.86% from the previous trading session.

OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know

OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -1.25% move from the prior day.

OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top

OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Gains As Market Dips: What You Should Know

In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.

Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab

Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.

OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union

OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.

OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?

OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.

Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates

Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know

OPKO Health (OPK) closed at $3.04 in the latest trading session, marking a -0.65% move from the prior day.

Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know

OPKO Health (OPK) closed at $2.87 in the latest trading session, marking a -1.37% move from the prior day.

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment

Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients

Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.